Migraine is a highly disabling neurological disorder that directly affects more than 1 billion
individuals worldwide. Available treatment options differ between countries and include …

Background Direct comparisons of the tolerability and safety of migraine preventive
treatments targeting the calcitonin gene-related peptide pathway are lacking. This study …

Objective To incorporate recent research findings, expert consensus, and patient
perspectives into updated guidance on the use of new acute and preventive treatments for …

Background The monoclonal antibody eptinezumab, which targets calcitonin gene-related
peptide, has shown migraine preventive effects starting the day following infusion and …

Objective To evaluate the efficacy and safety of eptinezumab, a humanized anti–calcitonin
gene-related peptide monoclonal antibody, in the preventive treatment of chronic migraine …

Objective To provide healthcare professionals with updated guidance in the use of novel
preventive and acute treatments for migraine in adults. Background The principles of …

Background Several novel treatments targeting the calcitonin gene-related peptide pathway
have been developed for migraine. We evaluated the efficacy of these medications …

Clinical trials are a key component of the evidence base for the treatment of headache
disorders. In 1991, the International Headache Society Clinical Trials Standing Committee …

Introduction Despite advances in the management of headache disorders, some patients
with migraine do not experience adequate pain relief with acute and preventive treatments. It …

The quality of clinical trials is an essential part of the evidence base for the treatment of
headache disorders. In 1991, the International Headache Society Clinical Trials Standing …